Optibrium Ltd.
- Home
- Companies
- Optibrium Ltd.
- Software
- Optibrium - Augmented Chemistry ...
Optibrium - Augmented Chemistry Software
FromOptibrium Ltd.
Cerella™ uses a unique deep learning approach to overcome limitations in drug discovery data, reducing costs and accelerating drug discovery cycles. Cerella highlights high-quality compounds with confidence, finding hidden opportunities caused by missing, uncertain or inaccurate data and prioritises the most valuable experiments.
Most popular related searches
Cerella offers cloud-enabled deployment, scaling from individual projects to global pharma databases. Data in the cloud are anonymised and fully encrypted in transit and at rest, and a multi-level security model controls access.
Cerella uses a unique, peer-reviewed deep learning method, with demonstrated successes in drug discovery.
Cerella™ is powered by Alchemite™, a deep learning method developed by Optibrium’s technology partner Intellegens Limited. In collaboration with pharmaceutical and biotechnology partners, Optibrium has rigorously demonstrated Alchemite’s unique benefits over conventional modelling methods in peer-reviewed studies, resulting in reductions in cost and time of discovery cycles. Cerella™ has proven its benefits in several collaborations with pharma and biotech organisations, working with individual project-level datasets up to global compound data repository level investigations.
Reducing the time and cost of your discovery cycles
Cerella can:
- Proactively highlight high-quality compounds by ‘filling in’ sparse data
- Increase confidence in decision making, identify hidden opportunities, flag outliers and false negatives
- Help you translate AI insights into the planning of experiments to focus on he most valuable measurements
- Enable you to gain more value from your compound data, accurately predicting complex endpoints, intractable with conventional QSAR modeling
- Add value at any scale, from individual project datasets to global compound data repositories